- Home
- DVAX vs GOODO Comparison
DVAX vs GOODO Comparison
Compare DVAX & GOODO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
GOODO
Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Current Price
Company Overview
Basic Information| Metric | DVAX | GOODO |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | 72 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | N/A |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | DVAX | GOODO |
|---|---|---|
| Price | $15.44 | $20.73 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $26.50 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | N/A |
| Earning Date | 02-19-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $330,514,000.00 | N/A |
| Revenue This Year | $24.63 | N/A |
| Revenue Next Year | $15.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.73 | N/A |
| 52 Week Low | $9.20 | N/A |
| 52 Week High | $15.49 | N/A |
Technical Indicators
Market Signals| Indicator | DVAX | GOODO |
|---|---|---|
| Relative Strength Index (RSI) | 89.03 | 61.36 |
| Support Level | $10.78 | $20.62 |
| Resistance Level | $15.43 | $21.29 |
| Average True Range (ATR) | 0.14 | 0.33 |
| MACD | 0.34 | 0.02 |
| Stochastic Oscillator | 98.97 | 63.30 |
Price Performance
Historical ComparisonAbout DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About GOODO Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.